FDA Brief

Warning letters Food

FDA warning letter to

Crown Wellness, Inc

High riskIssued Apr 29, 2021Posted May 11, 2021Center for Food Safety and Applied Nutrition

FDA warns Crown Wellness that its website and labels sell unapproved drugs, including chlorine dioxide claimed to treat COVID-19.

What happened

FDA reviewed www.crownwellness.com in February and March 2021 and found orders for products with claims that they treat diseases such as COVID-19, cancer, autism, and other conditions. The letter cites website pages, product labels, and testimonials as evidence that the products are intended as drugs. FDA says the products are unapproved new drugs and some lack adequate directions for use.

What FDA found

  1. Website and label claims that the products treat COVID-19, cancer, autism, and other diseases make them drugs under the law.

    FD&C Act section 201(g)(1)(B)/(C) [21 U.S.C. 321(g)(1)(B)/(C)]
  2. The products are new drugs because they are not generally recognized as safe and effective for those uses, and FDA has not approved them.

    FD&C Act sections 201(p), 301(d), 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]
  3. CLO2, E3 Renew Me/B.G. Blue Green Algae, DE, and Iodine Detoxified lack adequate directions for use because their intended diseases require a licensed practitioner.

    FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. Introducing these misbranded drugs into interstate commerce violates the law.

    FD&C Act section 301(a) [21 U.S.C. 331(a)]

What FDA wants

FDA asks the company to respond in writing within 15 working days describing corrective steps and documentation to prevent recurrence. If it believes the products are not in violation, it must include its reasoning and supporting information.

Who should pay attention

  • retailers and distributors that sell Crown Wellness products
  • supplement and wellness brands making disease-treatment claims online
  • companies marketing chlorine dioxide or COVID-19-related products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk